Cite

HARVARD Citation

    Toi, Y. et al. (2018). Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab. Oncologist. pp. 1358-1365. [Online]. 
  
Back to record